Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BioSante Pharmaceuticals Names Joy A. Thomas

Abstract:
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced the appointment of Joy A. Thomas as vice president of corporate development. Ms. Thomas will be integral to BioSante implementing its corporate development strategies, including collaborations and licensing.

BioSante Pharmaceuticals Names Joy A. Thomas

LINCOLNSHIRE, IL | Posted on September 5th, 2007

Ms. Thomas comes to BioSante after 13 years with Baxter Healthcare Corporation where she was most recently Senior Director, Global Strategy & Business Development for its Renal Division. Earlier she was Director, Strategic Marketing and Planning for its Medication Delivery Division. Ms. Thomas holds a Bachelor of Science degree in Finance and Russian from the University of Illinois, and a Master of Business Administration in International Business and Finance from the University of Chicago.

"We are very pleased to have Joy Thomas joining us at this exciting time for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer. "Joy's experience and expertise will be invaluable in assessing BioSante's strategic alternatives in view of the excellent progress we have made, especially related to FDA clarity on the development of LibiGel® in the treatment of female sexual dysfunction. We remain dedicated to our objective of maximizing stockholder value and believe Joy will be integral to this endeavor."

####

About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine.

For more information, please click here

Contacts:
BioSante Pharmaceuticals, Inc.
Phillip Donenberg
(847) 478-0500

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Northwestern scientists develop first liquid nanolaser: Technology could lead to new way of doing 'lab on a chip' medical diagnostics April 25th, 2015

Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

A silver lining: UCSB researchers cradle silver nanoclusters inside synthetic DNA to create a programmed, tunable fluorescent array April 23rd, 2015

Announcements

Northwestern scientists develop first liquid nanolaser: Technology could lead to new way of doing 'lab on a chip' medical diagnostics April 25th, 2015

Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

Pseudoparticles travel through photoactive material: KIT scientists measure important process in the conversion of light energy -- publication in Nature Communications April 24th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015

Nanofilm Appoints Senior Sales/Marketing Executives: Don Tecco, Director of Optical Sales, North America and Rex Talbott, Business Director Optical Products March 23rd, 2015

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project